Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes
- 105 Downloads
Purpose of review
Antiplatelet therapies are pivotal treatments in the management of acute coronary syndrome (ACS) with or without revascularization. In recent years, the use of P2Y12 antagonists prior to catheterization, so-called pretreatment, has been questioned, particularly in patients who may be at higher bleeding risks. The purpose of this review was to evaluate the current literature on contemporary and novel antiplatelet therapy in the pretreatment and treatment of ACS.
The P2Y12 receptor antagonists are associated with substantial reductions in morbidity and mortality for all types of ACS but only clopidogrel and ticagrelor have sufficient evidence for use in the pretreatment setting. The data regarding prasugrel support the use in patients undergoing percutaneous intervention (PCI). The glycoprotein IIa/IIIb antagonists are the most optimal for use in high-risk ACS as an adjuvant therapy during and after PCI.
In summary, although all P2Y12 antagonists have morbidity- and mortality-reducing effects in ACS, only clopidogrel and ticagrelor have sufficient evidence in the pretreatment setting. Newer antiplatelet therapies, most notably the protease-activated receptor 1 antagonists, are evolving and promising but are associated with greater bleeding risks.
KeywordsAntiplatelet P2Y12 Pretreatment ACS Coronary Ticagrelor
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 4.•• Bazemore TC, Nanna MG, Rao SV. Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. J Thromb Thrombolysis. 2017; Excellent review on pretreatment with antiplatelet therapyGoogle Scholar
- 7.Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337–43.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.•• Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228. Latest ACC guidelines for management of NSTE ACSCrossRefPubMedGoogle Scholar
- 13.Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J. 2005;150(6):1177–84.CrossRefPubMedGoogle Scholar
- 18.Goldstein P, Grieco N, Ince H, Danchin N, Ramos Y, Goedicke J, et al. Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry. Vasc Health Risk Manag. 2016;12:143–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv. 2015;8(1 Pt B):147–54.CrossRefPubMedGoogle Scholar
- 20.Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Scholler R, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol. 2012;101(4):305–12.CrossRefPubMedGoogle Scholar
- 24.Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, et al. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29(12):1495–503.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol. 2010;56(7):550–7.CrossRefPubMedGoogle Scholar
- 26.Ducci K, Grotti S, Falsini G, Angioli P, Liistro F, Mando M, et al. Comparison of pre-hospital 600 mg or 900 mg vs. peri-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial. Int J Cardiol. 2013;168(5):4814–6.CrossRefPubMedGoogle Scholar
- 28.Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J. 2005;150(6):1177–84.CrossRefPubMedGoogle Scholar
- 33.Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92–9.CrossRefPubMedGoogle Scholar
- 38.O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425.CrossRefPubMedGoogle Scholar
- 42.Food and Drug Administration. Center for Drug Evaluation and Research. 2009; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022307s000lbl.pdf. Accessed 29 Nov 2017.
- 47.James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, et al. Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX trial. JACC Cardiovasc Interv. 2016;9(18):1905–13.CrossRefPubMedGoogle Scholar
- 57.•• Geisler T, Booth J, Tavlaki E, Karathanos A, Muller K, Droppa M, et al. High platelet reactivity in patients with acute coronary syndromes undergoing percutaneous coronary intervention: randomised controlled trial comparing prasugrel and clopidogrel. PLoS One. 2015;10(8):e0135037. Summarizes the improvement in platelet reactivity following switch from clopidogrel to prasugrel in the setting of ACSCrossRefPubMedPubMedCentralGoogle Scholar
- 58.Caiazzo G, De Rosa S, Torella D, Spaccarotella C, Mongiardo A, Giampa S, et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv. 2014;7(1):104–12.CrossRefPubMedGoogle Scholar
- 59.•• Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J, et al. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep. 2015;5:13789. Summarizes the improvement in platelet reactivity following switch from clopidogrel to ticagrelor in the setting of ACSCrossRefPubMedPubMedCentralGoogle Scholar
- 60.clinicaltrials.gov. Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT01742117. Accessed 27 Nov 2017.
- 62.Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070–8.CrossRefPubMedGoogle Scholar
- 64.Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–87.CrossRefPubMedGoogle Scholar
- 65.Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000;101(7):751–7.CrossRefPubMedGoogle Scholar
- 66.The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997 May 17;349(9063):1429–35.Google Scholar
- 67.Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338(21):1488–97.Google Scholar
- 68.Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100(20):2045–8.CrossRefPubMedGoogle Scholar
- 69.Mehilli J, Kastrati A, Schulz S, Frungel S, Nekolla SG, Moshage W, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119(14):1933–40.CrossRefPubMedGoogle Scholar
- 73.Pan H, Boucher M, Kaunelis D. PAR-1 antagonists: an emerging antiplatelet drug class. CADTH issues in emerging health technologies Sep 2016; 148.Google Scholar
- 74.Capodanno D, Bhatt DL, Goto S, O’Donoghue ML, Moliterno DJ, Tamburino C, et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012 Oct;10(10):2006–15.CrossRefPubMedGoogle Scholar
- 75.Kosoglou T, Hunt TL, Xuan F, Kumar B, Statkevich P, Hanson ME, et al. Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: a randomized, placebo- and positive-controlled, parallel group trial. Clin Pharmacol Drug Dev. 2014;3(1):18–24.CrossRefPubMedGoogle Scholar
- 77.clinicaltrials.gov. Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT01742117. Accessed 27 Nov 2017.
- 78.clinicaltrials.gov. Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT01761786. Accessed 29 Nov 2017.